How CAR-Ts Are Changing The Lifecycle Paradigm For ATMPs
CAR T-cell therapies have resulted in the industry and regulators exploring unconventional approaches to collecting real-world safety and efficacy data from existing registries. Can this approach also work for other types of cell and gene therapy products in the future? Delegates at a conference in London explored the topic.
You may also be interested in...
A new scientific paper explains how companies can improve their post-licensing evidence generation plans by seeking scientific advice from EU regulators and health technology bodies at appropriate times during the drug development process.
The European Medicines Agency has identified key areas where stakeholders want to see it deliver a real change over the next five years.
A multi-stakeholder EU workshop has helped identify how patient registries can support the benefit-risk evaluation of CAR-T cell therapies, given the challenges posed by these products, not least the need for the long-term follow up of treated patients.